Development of a Novel Program to Facilitate Monitoring Physical Health and Adverse Effects in Children and Adolescents Prescribed Antipsychotic Medication

1. Walter G , DeLaroche A , Soh N , et al Side effects of second generation antipsychotics: the experience, views and monitoring practices of Australian child psychiatrists. Australasian Psychiatry, [epub ahead of print] 2008.

2. Australian Medicines Handbook Adelaide: Australian Medicines Handbook, 2008.

3. American Academy of Child and Adolescent Psychiatry . Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. Journal of the American Academy of Child & Adolescent Psychiatry 2001; 40 (Suppl. 7)S4–S23.

4. Lewis R . Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Canadian Journal of Psychiatry 1998; 43: 596–604.

5. Sikich L Hamer RM Bashford RA Sheitman BB Lieberman JA . A pilot study of risperidone, olanzapine and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004; 29: 133–145.

6. Martin A Scahill L Anderson GM . Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. American Journal of Psychiatry 2004; 161: 1125–1127.

7. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity . Consensus development conference on antipsychotic drugs and obesity and diabetes. Journal of Clinical Psychiatry 2004; 65: 267–272.

8. Marder SR Essock SM Miller AL . Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry 2004; 161: 1334–1349.

9. Lambert TJR Chapman LH . Diabetes, psychotic disorders and antipsychotic therapy; a consensus statement. Medical Journal of Australia 2004; 181: 544–548.

10. Remington G . Schizophrenia, antipsychotics, and the metabolic syndrome: is there a silver lining?. American Journal of Psychiatry 2006; 163: 1132–1134.

11. Department of Health and Ageing The National Strategy for Quality Use of Medicines. Canberra: Commonwealth of Australia, Department of Health and Ageing, 2002.

12. Grimshaw J Thomas R MacLennan G . Effectiveness and efficiency of guidelines dissemination and implementation strategies. Health Technology Assessment 2004; 8: 1–72.

13. Grimshaw J Shirran L Thomas R . Changing provider behaviour: an overview of systematic reviews of interventions. Medical Care 2001; 39 (Suppl. 2)2–45.

14. Grzeskowiak LE , Ellis DP , Phillips AJ , Angley MT. Monitoring physical health and adverse effects in children and adolescents prescribed antipsychotics. Journal of Pharmacy Practice and Research 2008; 38 (in press).